Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging agent could sharpen detection of rare tumors

NCT ID NCT02134639

First seen Jun 14, 2026 · Last updated Jun 17, 2026 · Updated 1 time

Summary

This early-phase study tested a new way to make a radioactive tracer called 68Ga-DOTATOC for PET-CT scans in 20 adults with suspected or known neuroendocrine tumors. The goal was to see if this new method could find tumors more accurately than the current standard scan (OctreoScan). Researchers also checked how reliable the tracer production was and whether it caused any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33076, France

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.